Zymeworks Inc. announced Dr. Jeffrey Smith has been promoted to Executive Vice President and Chief Medical Officer, where he will play a key role in leading the clinical development of early-stage programs and overseeing integrated global early-stage development group. Dr. John Fann has been promoted to Senior Vice President, Process Sciences, where he will continue to play a key role in supporting the advancement of new product candidates from preclinical studies into clinical trials.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.075 USD | -0.49% | +3.14% | -13.04% |
05-02 | Transcript : Zymeworks Inc., Q1 2024 Earnings Call, May 02, 2024 | |
05-02 | Zymeworks Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.04% | 650M | |
+3.59% | 106B | |
+7.02% | 23.47B | |
-14.75% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-9.41% | 16.78B | |
+5.27% | 14.41B | |
+37.37% | 12.86B | |
+328.13% | 8.78B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc Announces Additional Leadership Appointments